| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.694 | 9.170 | 12.554 | 7.976 | 3.545 | 9.576 | 20.508 | 27.275 | 31.334 | 32.420 |
| Total Income - EUR | 11.845 | 9.850 | 13.211 | 7.976 | 4.195 | 13.362 | 23.984 | 27.293 | 31.334 | 32.420 |
| Total Expenses - EUR | 11.714 | 9.479 | 12.935 | 7.861 | 4.151 | 19.754 | 23.165 | 25.870 | 23.970 | 28.216 |
| Gross Profit/Loss - EUR | 131 | 371 | 276 | 115 | 43 | -6.392 | 819 | 1.423 | 7.364 | 4.204 |
| Net Profit/Loss - EUR | 45 | 160 | 73 | 15 | 1 | -6.486 | 819 | 1.148 | 7.057 | 3.927 |
| Employees | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Medvirox S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 15.533 | 12.298 | 9.905 | 5.647 | 5.152 | 3.771 | 3.690 | 3.480 | 3.249 | 14.465 |
| Current Assets | 7.022 | 8.171 | 12.944 | 16.804 | 19.299 | 17.118 | 12.394 | 7.857 | 10.677 | 8.699 |
| Inventories | 5.435 | 7.490 | 10.291 | 14.401 | 18.540 | 14.681 | 9.293 | 6.138 | 6.360 | 7.332 |
| Receivables | 25 | 24 | 58 | 1.061 | 0 | 465 | 0 | 0 | 0 | 0 |
| Cash | 1.562 | 657 | 2.594 | 1.342 | 759 | 1.972 | 3.101 | 1.719 | 4.317 | 1.367 |
| Shareholders Funds | 90 | 249 | 318 | 328 | 323 | -6.170 | -5.214 | -4.082 | 2.987 | 6.898 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 22.465 | 20.220 | 22.531 | 22.122 | 24.129 | 27.059 | 21.297 | 15.420 | 10.938 | 16.266 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "9602 - 9602" | |||||||||
| CAEN Financial Year |
9602
|
|||||||||
Comments - Medvirox S.r.l.